<DOC>
	<DOCNO>NCT00440193</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , assessor-blind , event-driven , non-inferiority program efficacy study treatment duration 3 , 6 12 month patient confirm acute symptomatic DVT without symptomatic PE ( Einstein-DVT ) .</brief_summary>
	<brief_title>Oral Direct Factor Xa Inhibitor Rivaroxaban Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study</brief_title>
	<detailed_description>Within US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development , L.L.C . ' sponsor . The treatment period follow observational period 30 day start day last intake study medication , regardless actual duration study drug administration . Participants complete treatment period also enter observational period . It also possible participant enter observational period , e.g . due withdrawal consent termination study participation . Participants transfer study 11702 DVT ( NCT00440193 ) extension study 11899 ( NCT00439725 ) enter observational period .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Confirmed acute symptomatic proximal DVT without symptomatic PE Legal low age limitation ( country specific ) Thrombectomy , insertion caval filter , use fibrinolytic agent treat current episode DVT and/or PE Other indication VKA DVT and/or PE The prerandomization anticoagulant treatment ( Criteria # 4 ) prolong 36 hour maximum 48 hour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>